Welcome to our dedicated page for Aldeyra Therapeu SEC filings (Ticker: ALDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts, FDA correspondence, and cash runway details can hide deep inside Aldeyra Therapeutics’ filings—often across hundreds of pages. When a single 8-K can move the stock before the market opens, missing a paragraph is costly.
Stock Titan solves that problem. Our AI reviews every Aldeyra Therapeutics SEC document in real time, then surfaces what matters: from dry eye disease Phase 3 data buried in a 10-Q to non-obvious risk-factor tweaks inside the annual report 10-K. Plain-language summaries explain complex chemistry and clinical endpoints, so you can focus on decisions, not decoding jargon.
All filing types are here and updated the moment EDGAR releases them:
- Form 4 alerts for Aldeyra insider trading Form 4 transactions—know when executives buy or sell before milestones.
- 10-Q access for the latest Aldeyra quarterly earnings report 10-Q filing, including R&D spend trends and cash burn analysis.
- 10-K deep dives—our AI offers an Aldeyra annual report 10-K simplified view of pipeline strategy and funding needs.
- 8-K material events explained, translating regulatory feedback or trial updates into actionable context.
Use cases investors rely on every day:
- Track Aldeyra executive stock transactions Form 4 for alignment before data releases.
- Compare quarter-over-quarter cash runway without crunching spreadsheets.
- Receive instant alerts when a proxy statement discloses updated executive compensation.
Whether you’re researching “understanding Aldeyra SEC documents with AI” or need a quick take on the next catalyst, this page delivers clear, timely insight—no more wading through dense biotech prose.
Aldeyra Therapeutics (NASDAQ:ALDX) filed a Form 8-K reporting receipt of a Special Protocol Assessment (SPA) agreement letter from the FDA covering the pivotal trial design for ADX-2191, its investigational treatment for primary vitreoretinal lymphoma (PVRL). The SPA signals FDA concurrence that the study’s endpoints and analysis, if achieved, are sufficient for a future New Drug Application, materially reducing regulatory risk and potentially accelerating review. The related press release is furnished as Exhibit 99.1 under Item 7.01, with the same event noted under Item 8.01. No financial data, guidance, or operational changes were disclosed.
FAQ
What is the current stock price of Aldeyra Therapeu (ALDX)?
What is the market cap of Aldeyra Therapeu (ALDX)?
What is the primary focus of Aldeyra Therapeutics?
How does the company address ocular inflammatory diseases?
What differentiates Aldeyra Therapeutics from other biotech companies?
In which disease areas does Aldeyra Therapeutics have product candidates?
How does Aldeyra Therapeutics generate value in its market?
How does the research at Aldeyra Therapeutics support its product development?
